Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) Research & Development (2020 - 2025)

RxSight's Research & Development history spans 6 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 3.28% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $38.5 million, up 12.17%, while the annual FY2025 figure was $38.5 million, 12.17% up from the prior year.
  • Research & Development reached $8.9 million in Q4 2025 per RXST's latest filing, down from $9.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.4 million in Q1 2025 to a low of $5.4 million in Q3 2021.
  • Average Research & Development over 5 years is $7.6 million, with a median of $7.3 million recorded in 2023.
  • The largest YoY upside for Research & Development was 29.09% in 2021 against a maximum downside of 7.31% in 2021.
  • A 5-year view of Research & Development shows it stood at $5.9 million in 2021, then grew by 12.93% to $6.7 million in 2022, then rose by 9.88% to $7.3 million in 2023, then rose by 25.42% to $9.2 million in 2024, then fell by 3.28% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Research & Development are $8.9 million (Q4 2025), $9.1 million (Q3 2025), and $10.2 million (Q2 2025).